|
Bhag: Personally, I think that everyone's posts (except mine) have been great (objectivity, etc.). I'm having trouble understanding your post, however. Don't "boo-hoo" PI therapy. If I'm not mistaken (see post 4891), the doctor was taking a PI (I think I saw a bottle of Norvir on the table). Please read Dr. Oliver's posts about HIV/AIDS treatment. PI therapy is needed, IMO, without question, and I agree that Viracept will be the "gold standard." You haven't provided anything to refute this. In addition, it's certainly better to have an inventory of Viracept than to have a backlog and run out. Also, consider reading Yahoo IMNR BB; you need to get more current on Remune therapy. I suspect that next yr the standard combo treatment will be Viracept, Sustiva, Remune, + whatever new comes out. PS: VRTX reported terrible earnings & yet the stock was only down in fractions. Makes no sense to me whatsoever. And why is ENMD stock price higher than AGPH's. I would like to know if I get stock in AGPH #1 and AGPH #2 (like I received LU, NCR with the T breakup) AND, if new stock is issued, what basically happens to the current AGPH stock price? I assume it tanks further (to compensate). AND, when do we, as shareholders, vote? Maybe the shareholders will say "no." Then what happens? |
